Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Johnson & Johnson made materially false and/or misleading statements and/or failed to disclose that: J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation." Following this news, J&J's stock price fell over 2% on the same day.
In order to be eligible to join the JNJ class action lawsuit, you must have incurred a loss on shares of Johnson & Johnson purchased during the class period listed above.
TOP
